Stocks Health care TCRT
NASDAQ · Health careAlaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. brought in $3K of revenue over the twelve months to June 30, 2026, down 57.1% from a year earlier. It posted a net loss of $4M. In fiscal 2025 capital spending exceeded operating cash flow by $3M. At June 30, 2026 it held $124K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Alaunos Therapeutics, Inc.
- Net worth
- Alaunos Therapeutics, Inc. has a market value (market cap) of $4.2M at the latest share price, and shareholders' equity of $652K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $5K (-50.0% year on year), with a net loss of $4.2M. Over the 12 months to June 30, 2026: revenue $3K, net loss $4M.
- Cash flow
- In fiscal 2025 operations used $2.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Alaunos Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Alaunos Therapeutics, Inc. does
Alaunos Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TCRT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $5K | -$4.2M | -$2.20 | -$3M |
| 2024 | $10K | -$4.7M | -$2.92 | -$5M |
| 2023 | $5K | -$4.7M | -$21.97 | -$30.3M |
| 2022 | $2.9M | -$37.7M | -$26.06 | -$29.4M |
| 2021 | $398K | -$78.8M | -$56.73 | -$64.8M |
| 2020 | $0 | -$80M | -$58.26 | -$66.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TCRT ranks in Health care
Latest SEC filings
What Alaunos Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026Material agreement8-KAlaunos Therapeutics raised approximately $915,400.50 in net proceeds through a registered direct offering.
- September 17, 2026
- August 14, 2026
- July 6, 2026
- June 29, 2026Other event 8-K
- May 26, 2026Other event 8-K
- May 18, 2026Other event 8-K
- May 15, 2026
- April 30, 2026Annual report (amended) 10-K/A · period to December 31, 2025Revenue fell 50% to $5K versus the prior year; diluted EPS -$2.20 versus -$2.92.
- April 15, 2026
Insider trades
What the people running Alaunos Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 6, 2026 | Weis HolgerCEO | Received as pay | 4,363 | $8.8K |
| July 23, 2026 | Vieser JaimeDirector | Received as pay | 8,789 | $16.9K |
| July 23, 2026 | Postma Robert WDirector | Received as pay | 8,463 | $16.2K |
| July 23, 2026 | Weis HolgerCEO | Received as pay | 4,568 | $8.8K |
| July 23, 2026 | Jerman Michael AllenDirector | Received as pay | 8,138 | $15.6K |
| June 30, 2026 | Weis HolgerChief Executive Officer | Received as pay | 3,880 | $8.8K |
| June 12, 2026 | Weis HolgerChief Executive Officer | Received as pay | 7,761 | $17.5K |
| May 22, 2026 | Weis HolgerChief Executive Officer | Received as pay | 3,700 | $8.8K |
Who owns TCRT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Postma Robert W13D, may seek influence with 1 related filers | 9% | July 1, 2025 |
| Price Adrian13D, may seek influence with 20 related filers | 8.6% | March 5, 2026 |
Largest institutional holders
Insiders
4 insiders reported holding 155,493 shares in total, about $256.6K at the last price.
| Holder | Shares |
|---|---|
| Postma Robert WDirector | 58,609 |
| Vieser JaimeDirector | 47,642 |
| Weis HolgerCEO | 25,483 |
| Jerman Michael AllenDirector | 23,759 |
Questions about TCRT
What does Alaunos Therapeutics, Inc. do?
Alaunos Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TCRT. Its shares trade on NASDAQ under the ticker TCRT.
What is Alaunos Therapeutics, Inc.'s net worth?
Alaunos Therapeutics, Inc. has a market value (market cap) of $4.2M at the latest share price, and shareholders' equity of $652K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Alaunos Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $4M on revenue of $3K.
How much revenue does Alaunos Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Alaunos Therapeutics, Inc. reported revenue of $3K. That is 57.1% less than a year earlier.
When did Alaunos Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 22, 2026.
When is Alaunos Therapeutics, Inc.'s next earnings report?
Alaunos Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TCRT with
Follow TCRT
Get an email when Alaunos Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alaunos Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.